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Abstract
The most frequent site of metastasis in human prostate cancer (PCa) is the bone. Preferential adhesion of PCa
cells to bone-specific factors may facilitate the selective metastasis of the skeleton. The most abundant protein
within the skeleton is type I collagen. We previously demonstrated that PCa cells selected in vitro for collagen I
binding (LNCaPcol) are highly motile and acquired the capacity to grow within the bone compared to nontumori-
genic LNCaP parental cells. Treatment with α2β1-neutralizing antibodies selectively blocked collagen-stimulated
migration, suggesting that integrin signaling mediates PCa migration. To elucidate the mechanism of collagen-
stimulated migration, we evaluated integrin-associated signaling pathways in non–collagen-binding LNCaP pa-
rental cells and in collagen-binding isogenic C4-2B and LNCaPcol PCa cells. The expression and activity of RhoC
guanosine triphosphatase was increased five- to eightfold in collagen-binding LNCaPcol and C4-2B cells, respec-
tively, compared to parental LNCaP cells. RhoC activation was selectively blocked with antibodies to α2β1 where
treatment with a small hairpin RNA specific for RhoC suppressed collagen-mediated invasion without altering the
PCa cells’ affinity for collagen I. We conclude that the ligation of α2β1 by collagen I activates RhoC guanosine
triphosphatase, which mediates PCa invasion, and suggests a mechanism for the preferential metastasis of
PCa cells within the bone.
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Introduction
Selective adhesion of tumor cells to organ-specific protein factors
may influence organ-specific metastasis. The most abundant protein
within the bone is collagen type I, which comprises greater than 90%
of the total protein within the skeleton [1]. Prostate cancer (PCa)
metastasizes to the bone, specifically the pelvis, femur, and vertebral
bodies, in greater than 80% of patients [2]. We have previously dem-
onstrated that human PCa cells isolated from bone lesions bound
type I collagen with high affinity compared to PCa cells isolated from
soft tissue metastases [3]. Further, cells selected in vitro for collagen I
binding from nonmetastatic LNCaP PCa cells displayed increased
surface expression of the integrin collagen I receptor α2β1, exhibited
increased collagen-mediated migration, and acquired the ability to
grow within the bone [3]. These cells, LNCaPcol, were found to have
increased levels of active RhoC guanosine triphosphatase (GTPase),
thus suggesting that collagen I/α2β1 signaling mediates bone metas-
tasis of PCa cells through RhoC activation.
RhoC GTPase is one of three Rho isoforms that belong to the
Ras superfamily of small guanosine triphosphate (GTP) binding pro-
teins [4–6]. The members of this family cycle between an inactive
guanosine diphosphate (GDP)–bound and active GTP-bound states
that stimulate downstream effector proteins [7,8]. The Rho GTPases
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participate in the formation of contractile actin/myosin filaments
and therefore act as molecular switches involved in all aspects of cell
morphogenesis and cellular motility. Due to their involvement in
motility, Rho GTPases have been implicated in tumor progression
and metastasis. RhoC, in particular, was shown to participate in
the metastasis of several cancers including breast, pancreas, and mela-
noma [9–11]. We previously demonstrated that RhoC was expressed
in bone metastatic PC-3 PCa cells and was responsible for the inva-
sive capabilities of these cells [12].
The mechanism through which RhoC GTPase becomes activated
in metastatic cancer cells is unclear. Integrin engagement can stimu-
late integrin-linked kinase resulting in cytoskeletal reorganization
and signal transduction through the activation of the RhoA GTPase
[13–15]. Unlike RhoA, however, RhoC has not been previously
shown as a downstream effector of integrin signaling. In the present
study, we demonstrate that RhoC is activated on integrin α2β1 en-
gagement and regulates the collagen I–mediated invasion of PCa
cells. Activation of RhoC invasive programs after collagen I binding
suggests a mechanism for the preferential metastasis of PCa cells to
the skeleton where collagen I is in abundance.
Materials and Methods
Cells
LNCaP human prostate cancer cells were obtained from the
American Type Culture Collection (Rockville, MD). LNCaP cells
routinely fail to bind collagen type I in in vitro attachment assays
and are considered nontumorigenic in nude mice. LNCaPcol is an
isogenic variant of LNCaP PCa cells that was derived through suc-
cessive panning on type I collagen [3]. LNCaPcol cells have a high
affinity for collagen I with corresponding increases in α2β1 integrin
expression, collagen-mediated migration, and in vivo growth in bone
[3]. Cells were maintained in RPMI-1640 medium [10% fetal bovine
serum (FBS), 1 mM sodium pyruvate, 1× penicillin–streptomycin,
0.1 mM nonessential amino acids, 2 mM L-glutamine, and 1× vitamin
solution (Invitrogen, Carlsbad, CA)] in a 90% air, 10% CO2 atmo-
sphere at 37°C.
In Vitro Invasion Assay
PCa cells were grown to 75% confluence in T-75 tissue culture
flasks, harvested using nonenzymatic cell dissociation buffer (Sigma,
St. Louis, MO), and washed twice with Hank’s balanced salt solu-
tion to serum-free growth medium. Cells (2.75 × 105/0.25 ml) were
plated in duplicate to collagen I–coated, 3-μm Transwell inserts (BD
Biosciences, San Jose, CA). The lower chamber of the Transwell
contained normal growth medium with 10% serum. Transwells were
incubated for 16 hours at 37°C in a 10% CO2 incubator. Non-
migrated cells were removed from the upper chamber, and invaded
cells were stained with 1% methylene blue and counted under a light
microscope. For integrin blocking experiments, cells were harvested
and resuspended in a final concentration of 10 μg/ml α2β1 blocking
antibody (clone BHA2.1; Chemicon, Temecula, CA) or IgG1κ iso-
type control (BD Biosciences). Data are presented as mean ± SD
of duplicate wells from a representative experiment (n = 4).
In Vitro Monolayer Wound Assay
Glass coverslips, 25 mm in diameter, were coated with 1 μg/cm2
type I collagen (BD Biosciences) or with human fibronectin (BD Bio-
sciences) for 2 hours at 37°C. After this incubation, the coverslips were
washed three times with serum-free medium to remove excess pro-
tein and were placed in triplicate in six-well plates (Griener, VWR,
Bridgeport, NJ). PCa cells were harvested as previously mentioned
and were resuspended in a final concentration of 1 × 105 cells/ml. Ap-
proximately 1 ml of cell suspension was added to coverslips and al-
lowed to grow to confluence, approximately 2 days later. Once the
cells had reached confluence, a sterile 1000-μl pipette tip was used
to wound the cell monolayers across the length of the coverslip. The
ability of the cells to migrate on the matrix proteins and fill in the
scratch was followed for 16 hours.
Generation of Small Hairpin RNA–Expressing LNCaPcol Cells
Small hairpin RNA (shRNA) expression vector for RhoC was ob-
tained from Open Biosystems (Huntsville, AL). Lentivirus particles
containing the shRNA were generated by the University of Michi-
gan Vector Core and used to transduce LNCaPcol cells. Individual
shRhoC clones were selected, and expression of the RhoC and
homologous RhoA GTPases were determined by semiquantitative
reverse transcription–polymerase chain reaction using Fast SYBR
GreenER (Roche, Indianapolis, IN) on an Evocycler (Denville Scien-
tific, Metuchen, NJ). RhoC protein expression was determined by
Western blot analysis as previously described [12].
RhoC Activation Assay
The RhoC GTPase activation assay was performed using a modi-
fication of the G-LISA RhoA absorbance-based activation assay
(Cytoskeleton, Denver, CO). Briefly, LNCaP cells were grown to
75% confluence in 100-mm dishes and then serum-starved for
24 hours by incubating in serum-free medium. On the day of the
assay, cells were harvested using nonenzymatic cell dissociation buf-
fer (Sigma), washed twice in Hank’s balanced salt solution, and re-
suspended in serum-free medium to a final concentration of 1 ×
106 cells/ml. For each condition, 5 × 105 cells in a final volume of
2 ml were placed in 15-ml conical tubes and 0 or 10 μg/ml α2β1
blocking antibody (Chemicon) or IgG1κ isotype control (BD Bio-
sciences) was added and incubated for 15 minutes at 37°C with rock-
ing. After this incubation, 1 μg/ml human collagen I (Sigma) was
added, and the cells were incubated for an additional 15 minutes
at 37°C with rocking. At the end of the incubation period, all
cells were centrifuged gently, washed twice with ice-cold phosphate-
buffered saline (PBS), and resuspended in 65 μl of G-LISA lysis
buffer. Protein lysates were transferred to ice-cold 1.5-ml centrifuge
tubes and clarified by centrifuging at 10,000 rpm for 2 minutes. Pro-
tein concentrations were determined using the Precision Red Advance
Protein Assay (Cytoskeleton), and 1.0 mg/ml protein was used for the
GTPase activation assay as per manufacturer’s recommendations with
the exception that a RhoC-specific antibody [11] was substituted for
the supplied RhoA antibody. In preliminary experiments, the RhoC
antibody was titrated to yield optimal signal against 5 ng/well recom-
binant RhoC-GTPγS protein (a nonhydrolyzable form of GTP bound
to RhoC). A 1:50 dilution of the primary antibody and 1:250 dilution
of the horseradish peroxidase (HRP)–conjugated secondary antibody
were found to produce a RhoC-specific signal comparable to the
pan-Rho–specific signals produced by a pan-Rho antibody (Millipore,
Billerica, MA). After antibody and HRP detection reagent incuba-
tion, signals were detected on a Benchmark Plus microplate spectro-
photometer at 490 nm (Bio-Rad Laboratories, Hercules, CA). Data
analysis was performed using Prism 4.01 (GraphPad, San Diego, CA).
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Binding Assays
Binding assays were performed by seeding 5000 cells in 100 μl of
normal growth medium into fibronectin- or collagen I–precoated
96-well plates (BD Biosciences). At the 0, 5, 15, 30, and 60 minute
time points, wells were washed thrice with PBS, normal growth me-
dium was replaced, and 50 μl of 5 mg/ml MTT (Sigma) was added.
After 2 hours, the MTT-containing medium was removed, the cells
were lysed, and the formazan dye was solublized with the addition
of 100 μl of DMSO (Sigma). Absorbance values of the lysates were
determined on a microplate reader at 530 nm.
Immunofluorescence and Immunohistochemistry
LNCaPCol cells expressing either a scrambled shRNA control
(shScr) or shRNA to Rhoc (shRhoC) were grown on collagen I–coated
coverslips (BD Biosciences) until 70% confluence, serum-starved for
16 hours, stimulated with 10% FBS for 60 minutes, rinsed three times
with 1× PBS, pH 7.4, and fixed with 4% paraformaldehyde in PBS for
20 minutes at room temperature. After fixation, cells were rinsed three
times with 1× PBS and blocked with 5% normal goat serum (Jackson
ImmunoResearch Laboratories, West Grove, PA) in 1× PBS, pH 7.4,
with 0.3% Triton X-100 for 1 hour at room temperature. Immunofluo-
rescence was performed using fluorescein isothiocyanate–phalloidin
(Invitrogen Molecular Probes) in a humidified chamber. After rins-
ing with PBS, cells were treated with antifade (Invitrogen, Carlsbad,
CA), mounted onto SuperPlus slides (Corning, Corning, NY) with
Gel Mount (Biomedia, Foster City, CA), and sealed with clear nail
polish. Immunofluorescence was performed on a scanning laser con-
focal microscope (Zeiss, Thornwood, NY) housed in the University
of Delaware Department of Biological Sciences.
For immunohistochemistry, tibia sections were warmed to 60°C for
15 minutes, placed in xylene twice for 5 minutes, transferred to 100%
ethanol twice for 5 minutes, rehydrated in decreasing concentrations
of ethanol for 3 minutes each, and rinsed with ddH2O. Antigen re-
trieval was performed by simmering sections in citrate buffer, pH 6.0,
for 10 minutes in a microwave followed by a 5-minute incubation
with H2O2 to block endogenous peroxidases. Primary antibodies, rab-
bit anti-RhoC (1:150) [16], anti–prostate-specific antigen (PSA,
1:500), or IgG control were diluted in 5% BSA/PBS and incubated
overnight at 4°C. After this incubation, the sections were treated for
10 minutes with a biotin link and streptavidin–nickel. Colorimetric
visualization was performed with the addition of DAB–peroxidase sub-
strate solution for 10 minutes followed by rinsing. Slides were counter-
stained with 2% w/v methyl green in 0.1 M NaOAc, pH 4.2,
coversliped using Clear-Mount (EMS, Hatfield, PA), and sealed with
clear nail polish. Imaging was performed on a fluorescence microscope
(Axioscope; Zeiss) at a magnification of ×10.
Results
Blocking α2β1 Decreases Collagen-Mediated Invasion
Fragments of type I collagen were shown to induce chemotactic
migration of several tumor cell lines and endothelial cells [17,18].
We sought to define the role of α2β1 integrin in collagen-stimulated
directional and random motility using nonmetastatic parental LNCaP
PCa cells and bone metastatic LNCaPcol cells. LNCaPcol cells were de-
rived from LNCaP cells and have elevated α2β1 expression and colla-
gen I attachment [3]. Therefore, when plated on collagen I, LNCaPcol
cells were stimulated to invade three-fold over parental LNCaP cells,
which had a low collagen-stimulated invasion (P < .0001; Figure 1A).
Pretreating cells with a neutralizing antibody to the α2β1 complex de-
creased the invasion of both LNCaP and LNCaPcol cells compared to
IgG isotype control antibody treated cells (P < .003 and P < .0001,
respectively; Figure 1A). Further, treatment with neutralizing α2β1
antibody decreased LNCaPcol collagen-stimulated invasion to that
of basal LNCaP cells, indicating that the invasion was mediated
by α2β1. The ability to induce migration was specific to collagen
I/α2β1 signaling. In vitro monolayer wound assays demonstrated that
LNCaPcol cells plated on collagen were stimulated to migrate into the
cleared region within 16 hours where cells plated on plastic or fibro-
nectin failed to migrate (Figure 1B). These data suggest that the signal
transduction pathways activated by integrins differ depending on the
Figure 1. Blocking α2β1 decreases collagen-mediated invasion.
(A) In vitro invasion through collagen I. PCa cells (2.75 × 105) in
serum-free medium were plated to 3-μm collagen I–coated in-
serts and placed in wells containing 10% FBS growth medium
for 16 hours. A final concentration of 10 μg/ml of α2β1 blocking
antibody or IgG control was added to the cells at plating as in-
dicated. After this incubation, migrating cells were stained with
methylene blue, and the total number of migrating cells/filter
was quantified under a magnification of ×10. Data are presented
as mean ± SD of duplicate wells from a representative experiment
(n = 4). White bars indicate untreated; light gray bars, IgG control;
dark gray bars, α2β1 blocking antibody–treated cells: *P < .001
compared to LNCaP cells; ^P < .003 and #P < .001 compared
to isotype control cells. (B) In vitro monolayer migration wound
assay. Cells (1 × 106/ml) were plated to collagen I– or fibronectin-
coated coverslips and allowed to grow to confluence. At that time,
a channel was scraped in the monolayers, and the ability of the cells
to migrate on the matrix proteins was followed for 16 hours.
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integrin pairs involved and that the ligation of α2β1 specifically stimu-
lates invasive programs in PCa cells.
Blocking α2β1 Decreases RhoC GTPase Activation
In vitro invasion assays suggest that α2β1-mediated signaling in-
duces cellular migration programs. Analysis of integrin-associated
signaling pathways revealed that the expression and activity of Fak
and the Src family kinases (Src, Lyn, and Yes) did not differ within
LNCaPcol cells (data not shown). We have previously demonstrated
using immunoblot analysis that both the active and total amounts of
RhoC GTPase were increased in collagen I–binding LNCaPcol and
C4-2B PCa cells compared to parental LNCaP cells [3]. To enable
accurate quantification of RhoC activity, an ELISA-based colorimet-
ric assay for RhoA activity was modified to evaluate GTP-bound or
active RhoC protein in LNCaPcol cell lysates. RhoC GTPase activity
was optimally detected with a 1:50 dilution of a RhoC-specific pri-
mary antibody (Figure 2). Treatment of LNCaPcol cells in suspension
with soluble type I collagen increased the active form of RhoC pro-
tein sixfold compared to untreated cells (P < .0001; Figure 3A).
Binding of LNCaPcol to fibronectin did not increase RhoC activa-
tion (data not shown). Pretreatment with neutralizing antibody to
α2β1 specifically and selectively reduced type I collagen activation
of RhoC protein by fivefold in LNCaPcol cells compared to IgG-
treated collagen-stimulated cells, confirming that α2β1 mediated the
observed increase in RhoC, P < .0028 (Figure 3B). To our knowledge,
this is the first report to demonstrate that α2β1 integrin ligation by
collagen I stimulates the activation of RhoC GTPase.
Blocking RhoC Decreases Collagen-Mediated Invasion
To directly test whether RhoC mediates collagen-stimulated in-
vasion of PCa cells, an shRNA specific to RhoC were transfected into
LNCaPcol cells and the effect on collagen I–mediated invasion was
measured. Western blot analysis confirmed the complete loss of total
RhoC protein expression in the shRhoC cells relative to untrans-
fected and shcontrol LNCaPcol cells (Figure 4A). As previously
reported, no effect was seen on the expression of RhoA GTPase
(data not shown) [19]. Reducing RhoC protein expression with
shRNA decreased in vitro invasion from 75% to 50% compared to
untransfected and shcontrol LNCaPcol cells, respectively, thus con-
firming that RhoC mediates collagen I–stimulated invasion (P <
.005; Figure 4B).
Evidence from other laboratories suggest that Rho GTPase activa-
tion can lead to a refinement in the affinity of integrin binding to
substrates such as type I collagen [20]. To determine whether the
decreased invasiveness of shRhoC-transfected cells was due to a re-
duced affinity for type I collagen, collagen I binding assays were per-
formed (Figure 4C ). shRhoC-transfected cells bound both collagen I
and fibronectin comparably to shcontrol cells, demonstrating that
the affinity for collagen I was unaffected by RhoC knock-down at
60 minutes (P = .3679 and P = .5472, respectively). However, dis-
tinct changes in cell morphology due to alterations in the actin cyto-
skeleton were apparent (Figure 4D). Inhibition of RhoC expression
led to a profound transition from an epithelial morphology to a
spindle-like morphology reminiscent of what was observed in PC-3
PCa cells transfected with a dominant-negative RhoC [12].
We previously demonstrated that the LNCaPcol cells could grow in
the tibias of nude mice [3]. To examine whether RhoC expression
Figure 2. Optimization of RhoC activation assay. The G-LISA RhoA,
B, and C absorbance-based GTPase activation assay was opti-
mized for detecting active RhoC GTPase. Recombinant RhoC pro-
tein was labeled with nonhydrolyzable GTPγS, and 5 ng of protein
was used per assay well. A 1:250 dilution of pan-Rho antibody
was compared with decreasing antibody dilutions of a polyclonal
RhoC-specific antibody, and a 1:250 dilution of an HRP-conjugated
antirabbit secondary antibody. Absorbance was read at 490 nm,
and data are presented as the mean ± SD of triplicate wells from
a representative experiment (n = 3).
Figure 3. Blocking α2β1 decreases RhoC GTPase activation. (A)
Collagen stimulation increases RhoC activation. LNCaPcol cells
were treated in suspension with 1 μg/ml type I collagen for 15 min-
utes before lysis and were analyzed for RhoC. Data are presented
as the fold increase over parental LNCaP control. (B) Blocking α2β1
integrin (dark gray bars) decreases active RhoC compared to un-
treated (white bars) or IgG control (light gray bars). Experiments in
A were repeated in the presence of 10 μg/ml neutralizing antibody
to α2β1 or IgG control and were evaluated for active RhoC protein
(n = 4), *P < .0028.
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correlated with the formation of PCa bone lesions, tibias obtained
from this published study were stained for PSA, to mark PCa cells,
and RhoC. All PSA-positive bone lesions, whether produced by
LNCaP (not shown) or LNCaPcol cells, stained positive for RhoC
GTPase protein expression (Figure 4E ). Viewed together, the data
show that blocking α2β1 decreases RhoC GTPase activation, which
reduces collagen I–stimulated invasion. As type I collagen is the
major protein component of the bone, these observations suggest
a possible mechanism for the selective metastasis of PCa cells to
the skeleton.
Figure 4. Blocking RhoC decreases collagen-mediated invasion. (A) Western blot for RhoC protein. RhoC protein expression was de-
termined by Western blot analysis as previously described [12]. (B) shRNA to RhoC decreases collagen-stimulated invasion. Human
LNCaP and LNCaPcol PCa cells were viral-transduced with shRNA molecules RhoC. Transduced cells were plated to collagen-coated
invasion chambers, and the extent of invasion was measured after 16 hours. Shown are means ± SD of duplicated wells from a rep-
resentative assay (n= 3), *P< .005. (C) RhoC knock-down does not alter collagen attachment. Untransfected (white bars), shScr control
(light gray bars), and shRNA RhoC–transfected cells (dark gray bars) were plated to fibronectin- or collagen I–coated wells and were
allowed to attach for 15, 30, and 60 minutes, respectively, before thorough washing. The number of adherent cells was determined
by MTT staining (P < .3670 and P < .5472, respectively). (D) RhoC knock-down alters cell morphology and actin cytoskeleton. Control
shScr and shRhoC LNCaPcol cells were plated on collagen I–coated coverslips, stained with fluorescein isothiocyanate–phalloidin, fixed,
and mounted. Shown are phase contrast and immunofluorescent images taken using a confocal microscope at a magnification of ×40.
Images are representative of three separate experiments. (E) PSA and RhoC expression overlap in PCa bone lesions. Bone tumors gen-
erated after intratibial injection were stained for PSA, to identify PCa cells, and RhoC GTPase by standard immunohistochemistry.
Shown are representative lesions of 20.
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Discussion
Patients with PCa who die of their disease do so because of the
metastatic spread of the tumor cells from the prostate to distant organ
sites [21]. A prerequisite for metastatic spread is the ability of the
tumor cell to reorganize the cytoskeleton to allow cellular motility. The
Rho GTPases comprise a large family of monomeric GTP-binding
proteins that are required for cytoskeletal rearrangement [15,22,23].
These proteins are overexpressed in multiple cancers and are linked
to enhanced metastatic potential [4–6]. In particular, the expression
of RhoC GTPase is associated with poor prognosis in breast and lung
cancers [24,25]. Overexpression of RhoC in human mammary epithe-
lial cells and murine lung cancer cells significantly enhanced the me-
tastasis of transfected cells [24]. Inhibition of RhoC GTPase function
within these cells through the stable expression of a dominant-negative
protein decreased in vitro invasion and experimental metastasis in vivo
[12,24,25]. Consistent with its role in motility, knock-out of RhoC in
PyV-mT transgenic mice did not affect tumor development but led to
the inhibition of metastasis by decreasing the motility and survival of
metastatic cells [26]. The mechanism through which RhoC is thought
to regulate motility is through the activation of both the mitogen-
activated protein kinase (MAPK) and PI-3 kinase (PI3K) pathways.
Specifically, RhoC affects tumor cell motility and invasion through
the activation of MAPK where RhoC GTPase activation of PI3K af-
fects attachment independent of growth [27]. The mechanism by
which RhoC becomes activated in tumor cells, however, is yet unclear.
Integrins are a large family of proteins, which mediate adhesion to
extracellular matrix proteins and link the extracellular matrix to the
cytoskeleton [28]. Integrins have been shown to control cell survival,
proliferation, differentiation, and metastasis through the activation
of intracellular signaling molecules including Src, Fak, MAPK, and
PI3K [29–32]. We have previously shown that PCa cells isolated
from the bone both adhered to and were chemotactic toward to type
I collagen compared to cells isolated from soft tissue lesions [3]. The
increased adherence and migration was attributed to increased sur-
face expression of the integrin collagen receptor α2β1 as neutralizing
antibodies to α2β1 blocked collagen-mediated properties [3]. In the
present study, we report that α2β1 directs collagen I–stimulated in-
vasion through an increased activity of the RhoC GTPase. We found
that not only did the basal levels of total and active RhoC increase in
collagen-binding cells compared to control cells but also that treat-
ment with collagen I increased the amount of active RhoC protein
within collagen-binding cells. Treatment with neutralizing antibodies
to α2β1 decreased both active RhoC levels and collagen-stimulated
in vitro invasion. Transfection with shRNA specific to RhoC blocked
collagen-stimulated invasion demonstrating that α2β1 signaling me-
diates collagen invasion through the up-regulation of RhoC. We
further report that matrix-stimulated motility was specific to type I
collagen in that cells plated on fibronectin failed to migrate. These
data are consistent with previously published reports, which showed
that the migration of MDCK cells was inhibited on fibronectin but
stimulated when plated on collagens by signaling through the Rho
family member Rac GTPase [33].
The activation of RhoC GTPase through collagen I/α2β1 signal
transduction suggests a novel pathway for PCa metastasis to the
bone. As the bone is rich in collagen I, PCa cells that express high
levels of α2β1 would be stimulated to invade the bone through RhoC
activation. Collectively, these data support a model in which α2β1
integrin-mediated collagen adhesion plays a fundamental role in
the ability of PCa cells to metastasize to the bone microenvironment.
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